GLP1R and Hepatic steatosis: CNTO3649, a GLP-1 analog, after being continuously administered subcutaneously to APOE*3-leiden transgenic mice, fed on a high fat die, markedly reduced very low-density lipoprotein production and hepatic steatosis, in addition to improving glycemic control [24].